Table 1 Characteristics of patients in the Gene expression analysis, Radiogenomics discovery cohort, radiogenomics validation cohort, immune phenotype cohort and Immunotherapy-treated cohort
Variables | Gene expression analysis cohort | Radiogenomics discovery cohort | Radiogenomics validation cohort | Immune phenotype cohort | Immunotherapy-treated cohort | |||||
|---|---|---|---|---|---|---|---|---|---|---|
n = 1089 | n = 94 | n = 24 | n = 158 | N = 77 | ||||||
N | % | N | % | N | % | N | % | N | % | |
Age (years) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 18–60 | 600 | 55.1 | 62 | 66 | 18 | 75 | 121 | 76.6 | 67 | 87 |
 > 60 | 489 | 44.9 | 32 | 34 | 6 | 25 | 37 | 23.4 | 10 | 13 |
Laterality | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Left | 567 | 52.1 | 50 | 53.2 | 10 | 41.7 | 89 | 56.3 | 51 | 66.2 |
 Right | 522 | 47.9 | 44 | 46.8 | 14 | 58.3 | 69 | 43.7 | 26 | 33.8 |
Status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Alive | 938 | 86.1 | 91 | 96.8 | 24 | 100 | NA | NA | NA | NA |
 Dead | 151 | 13.9 | 3 | 3.2 | 0 | 0 | NA | NA | NA | NA |
OS (years) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 ≤ 1 | 168 | 15.4 | 6 | 6.3 | 1 | 4.2 | NA | NA | NA | NA |
 > 1 ≤ 3 | 481 | 44.2 | 44 | 46.3 | 6 | 25 | NA | NA | NA | NA |
 > 3 ≤ 5 | 187 | 17.2 | 24 | 25.3 | 8 | 33.3 | NA | NA | NA | NA |
 > 5 years | 253 | 23.2 | 21 | 22.1 | 9 | 37.5 | NA | NA | NA | NA |
Pathologic stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 I | 180 | 16.5 | 20 | 21.3 | 8 | 33.3 | 6 | 3.8 | 0 | 0 |
 II | 620 | 57 | 59 | 62.7 | 15 | 62.5 | 57 | 36.1 | 19 | 24.7 |
 III | 248 | 22.8 | 15 | 16 | 1 | 4.2 | 23 | 14.5 | 12 | 15.6 |
 IV | 20 | 1.8 | 0 | 0 | 0 | 0 | 2 | 1.3 | 0 | 0 |
 X | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 NA | 21 | 1.9 | 0 | 0 | 0 | 0 | 70 | 44.3 | 46 | 59.7 |
Estrogen receptor | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Positive | 802 | 73.6 | 78 | 83 | 19 | 79.2 | 119 | 75.3 | 15 | 19.5 |
 Negative | 237 | 21.8 | 16 | 17 | 5 | 20.8 | 39 | 24.7 | 58 | 75.3 |
 Indeterminate | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 NA | 50 | 4.6 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5.2 |
Progesterone receptor | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 Positive | 693 | 63.6 | 72 | 76.6 | 15 | 62.5 | 100 | 63.3 | 15 | 19.5 |
 Negative | 343 | 31.5 | 22 | 23.4 | 9 | 37.5 | 58 | 36.7 | 58 | 75.3 |
 Indeterminate | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 NA | 53 | 4.9 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5.2 |
Human epidermal growth factor receptor 2 | ||||||||||
 Positive | 164 | 15.1 | 11 | 11.7 | 2 | 8.4 | 118 | 74.7 | 6 | 7.8 |
 Negative | 559 | 51.3 | 48 | 51.1 | 14 | 58.3 | 40 | 25.3 | 67 | 87 |
 Indeterminate | 190 | 17.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
 NA | 176 | 16.2 | 35 | 37.2 | 8 | 33.3 | 0 | 0 | 4 | 5.2 |